July 8, 2021
Chugai Pharmaceutical said on July 7 that it has filed an application seeking an additional indication for its PD-L1 inhibitor Tecentriq (atezolizumab) for the adjuvant treatment of non-small cell lung cancer (NSCLC) in Japan. The submission rides on the back...read more